Skip to main content
Medical information Clinical review pending

Genetic Testing

GALNT3 Gene Tumoral Calcinosis Hyperphosphatemic Familial Type 1 Genetic Test

Genetic test using Next Generation Sequencing (NGS) to identify mutations in the GALNT3 gene associated with Tumoral Calcinosis, Hyperphosphatemic Familial Type 1. Helps understand genetic risk and guide management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (typically collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
Results
Results are typically available within 3 to 4 weeks. Confirm the current turnaround time with the laboratory before booking.
Preparation
No special preparation is usually required for a blood draw. However, confirm with the laboratory for any specific instructions.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the GALNT3 Gene Tumoral Calcinosis Hyperphosphatemic Familial Type 1 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Symptoms suggestive of tumoral calcinosis (e.g., painful swelling near joints, skin lesions).
  • ✓Family history of tumoral calcinosis or related metabolic disorders.
  • ✓Diagnosis confirmation when clinical findings are unclear.
  • ✓Genetic counseling for individuals and families affected by the condition.
  • ✓Assessment of risk for family members of an affected individual.
02

In plain language

What this test helps you understand

This test identifies mutations in the GALNT3 gene, which can confirm a diagnosis of Tumoral Calcinosis, Hyperphosphatemic Familial Type 1. It helps healthcare providers understand the genetic basis of the condition, potentially guiding management strategies and informing family members about their risk.
The GALNT3 Gene Tumoral Calcinosis Hyperphosphatemic Familial Type 1 NGS Genetic DNA Test is a diagnostic tool used to identify genetic mutations linked to tumoral calcinosis. This condition involves abnormal calcium deposits in tissues, often associated with high phosphate levels. The test uses Next Generation Sequencing (NGS) technology to analyze the GALNT3 gene, which is involved in phosphate regulation. Understanding genetic factors can help in managing the condition and assessing risks for family members. This test is particularly relevant for individuals with symptoms suggestive of tumoral calcinosis or a family history of the disorder.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is usually required for a blood draw. However, confirm with the laboratory for any specific instructions.
SampleBlood sample (typically collected in an EDTA tube). Confirm specific requirements with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) of the GALNT3 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes specific mutations within the GALNT3 gene. It may not detect all possible genetic variations associated with tumoral calcinosis. A negative result does not completely rule out the condition. Interpretation requires clinical correlation.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Tumoral Calcinosis is a rare genetic disorder characterized by the formation of large calcium deposits (tumors) in tissues, often around joints and in the skin. It is frequently associated with high levels of phosphate in the blood.
The GALNT3 gene provides instructions for making an enzyme involved in the process of adding sugar molecules (glycosylation) to proteins. Mutations in this gene can disrupt phosphate metabolism, leading to Tumoral Calcinosis.
Individuals experiencing symptoms like painful lumps near joints or skin lesions, or those with a family history of Tumoral Calcinosis, should discuss this test with their doctor.
A healthcare professional will interpret the test results in the context of your medical history and symptoms. They will explain the significance of any identified genetic mutations.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
You can book the test by contacting the laboratory directly via phone or WhatsApp at +254711564616. Home sample collection may be available.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp